Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Receivables - Accured (2020 - 2023)

Silo Pharma (SILO) has disclosed Receivables - Accured for 4 consecutive years, with $9600.0 as the latest value for Q3 2023.

  • Quarterly Receivables - Accured rose 100.0% to $9600.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $9600.0 through Sep 2023, up 100.0% year-over-year, with the annual reading at $6010.0 for FY2022, 2.44% down from the prior year.
  • Receivables - Accured hit $9600.0 in Q3 2023 for Silo Pharma, up from $8390.0 in the prior quarter.
  • In the past five years, Revenue - Other ranged from a high of $85733.0 in Q1 2022 to a low of $3000.0 in Q2 2020.
  • Historically, Receivables - Accured has averaged $8445.9 across 4 years, with a median of $6160.0 in 2021.
  • Biggest five-year swings in Receivables - Accured: crashed 77.9% in 2021 and later skyrocketed 200.46% in 2023.
  • Year by year, Receivables - Accured stood at $27876.0 in 2020, then plummeted by 77.9% to $6160.0 in 2021, then decreased by 2.44% to $6010.0 in 2022, then skyrocketed by 59.73% to $9600.0 in 2023.
  • Business Quant data shows Receivables - Accured for SILO at $9600.0 in Q3 2023, $8390.0 in Q2 2023, and $7193.0 in Q1 2023.